Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | DAO | P14920 | 2/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31122027 | 1.00 | ADORA3 (0.45) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL7319991 | 0.84 | KIF11 (0.38) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL10505582 | 0.81 | ADORA3 (0.50) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL2086838 | 0.78 | DAO (0.42) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL13954881 | 0.77 | DAO (0.64) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL13015480 | 0.75 | DAO (0.66) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL16819122 | 0.75 | HSD11B1 (0.51) | LMNADAODRD2HSD11B1HTT | |
| SCHEMBL26067685 | 0.75 | HSD11B1 (0.51) | LMNADRD2HSD11B1HTTMAPK1 | |
| SCHEMBL22605911 | 0.74 | HTR1A (0.39) | DAOHTR1ADRD2DRD3AXL | |
| SCHEMBL13015488 | 0.74 | DAO (0.50) | ADORA3ADORA2AADORA2BADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| CN-112979631-A | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10995073-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476278-B2 | Thiazole Derivatives as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | SCHERING CORPORATION | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331313-A1 | Thiazole Derivatives as Protein Kinase Inhibitors | DAPK2, DAPK1, JAK1 | ADORA3 3997/4885ADORA2A 3870/4885ADORA2B 4410/4885 |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | PARP11, PARG, PARP16 | ADORA3 487/4885ADORA2A 1134/4885ADORA2B 221/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ADORA3 452/4885ADORA2A 1100/4885ADORA2B 200/4885 |
| US-10995073-B2 | PARG inhibitory compounds | PARG, PARP11, PARP16 | ADORA3 452/4885ADORA2A 1100/4885ADORA2B 200/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | ADORA3 487/4885ADORA2A 1134/4885ADORA2B 221/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ADORA3 452/4885ADORA2A 1100/4885ADORA2B 200/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | ADORA3 452/4885ADORA2A 1100/4885ADORA2B 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.